Shree Ganesh Biotech India Analysis

dividend

Pros

Cons

• Unable to evaluate Shree Ganesh Bio-Tech (India)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Shree Ganesh Bio-Tech (India)'s dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Shree Ganesh Bio-Tech (India) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Shree Ganesh Bio-Tech (India) is profitable, therefore cash runway is not a concern.
• Shree Ganesh Bio-Tech (India) is profitable, therefore cash runway is not a concern.
• Debt is covered by short term assets, assets are 110.3x debt.
• Shree Ganesh Bio-Tech (India)'s cash and other short term assets cover its long term commitments.
• Shree Ganesh Bio-Tech (India)'s level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
• Low level of unsold assets.

Cons

• Operating cash flow is negative therefore debt is not well covered.

management

Pros

Cons

• The average tenure for the Shree Ganesh Bio-Tech (India) board of directors is less than 3 years, this suggests a new board.

misc

Pros

Cons

• Shree Ganesh Bio-Tech (India) is not covered by any analysts.
• BSE:539470 has not traded for 29 days.

past

Pros

Cons

• Shree Ganesh Bio-Tech (India)'s 1-year earnings growth is negative, it can't be compared to the 5-year average.
• Shree Ganesh Bio-Tech (India)'s year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
• Shree Ganesh Bio-Tech (India) used its assets less efficiently than the IN Food industry average last year based on Return on Assets.
• Shree Ganesh Bio-Tech (India)'s use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
• Shree Ganesh Bio-Tech (India) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
• Shree Ganesh Bio-Tech (India)'s 1-year earnings growth is negative, it can't be compared to the IN Food industry average.

value

Pros

Cons

• Shree Ganesh Bio-Tech (India) is overvalued based on assets compared to the IN Food industry average.
• Shree Ganesh Bio-Tech (India) is overvalued based on earnings compared to the IN Food industry average.
• Shree Ganesh Bio-Tech (India) is overvalued based on earnings compared to the India market.
• BSE:539470 is flat (0%) underperforming the Food industry which returned 5% over the past month.
• BSE:539470 is flat (0%) underperforming the market in India which returned 8% over the past month.